帕金森病的诊断和治疗进展

doi:10.3969/j.issn.1003-9198.2025.02.002

摘要/Abstract

摘要： PD是一种常见的神经退行性疾病,主要影响病人的运动功能,并伴随一系列非运动症状,严重影响病人的生活质量。随着人口老龄化的加剧,PD的发病率不断上升,其早期诊断和有效治疗的重要性愈发突出。近年来,针对PD的诊断和治疗方法取得了显著进展,特别是在早期诊断技术、药物治疗、手术治疗及新兴疗法方面。例如,影像学技术的进步使得早期识别PD成为可能,而新一代药物的问世则为病人提供了更多的治疗选择。此外,脑深部电刺激等手术治疗方法在改善运动症状上展现了良好的效果。本文将对这些进展进行综述,旨在为临床工作提供新的见解和启示。

关键词: 帕金森病, 诊断, 药物治疗, 非药物治疗

Abstract: Parkinson's disease (PD) is a common neurodegenerative disease that primarily affects the motor functions of patients and is accompanied by a range of non-motor symptoms, severely impacting the quality of life. With the aging population, the incidence of PD continues to rise, highlighting the importance of early diagnosis and effective treatment. In recent years, significant progress has been made in the diagnosis and treatment of PD, particularly in the development of early diagnostic techniques, pharmacological treatments, surgical interventions and emerging therapies. For example, advancements in imaging technology have made early identification of PD possible, while the emergence of new generation drugs has provided patients with more treatment options. Additionally, surgical treatments such as deep brain stimulation have shown good results in improving motor symptoms. This article will discuss these advancements, aiming to provide new insights and inspiration for clinical practice and promote the development of comprehensive management and treatment strategies for PD.

Key words: Parkinson's disease, diagnosis, pharmacological treatment, non-pharmacological treatment

中图分类号:

R 742.5

孙高慧, 冯美江. 帕金森病的诊断和治疗进展[J]. 实用老年医学, 2025, 39(2): 110-115.

SUN Gaohui, FENG Meijiang. Advance in the diagnosis and treatment of Parkinson's disease[J]. Practical Geriatrics, 2025, 39(2): 110-115.

参考文献

[1] SAITOH Y, TAKAHASHI K. Current pharmacological treatment for Parkinson's disease[J]. Brain Nerve, 2023, 75(5): 441-449.
[2] POSTUMA R B, BERG D, STERN M, et al. MDS clinical diagnostic criteria for Parkinson's disease[J]. Mov Disord, 2015, 30(12): 1591-1601.
[3] BERG D, POSTUMA R B, ADLER C H, et al. MDS research criteria for prodromal Parkinson's disease[J]. Mov Disord, 2015, 30(12): 1600-1611.
[4] HEINZEL S, BERG D, GASSER T, et al. Update of the MDS research criteria for prodromal Parkinson's disease[J]. Mov Disord, 2019, 34(10): 1464-1470.
[5] MAHLKNECHT P, GASPERI A, DJAMSHIDIAN A, et al. Performance of the movement disorders society criteria for prodromal Parkinson's disease: a population-based 10-year study[J]. Mov Disord, 2018, 33(3): 405-413.
[6] PILOTTO A, HEINZEL S, SUENKEL U, et al. Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts[J]. Mov Disord, 2017, 32(7): 1025-1034.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组, 中国医师协会神经内科医师分会帕金森病及运动障碍病专业委员会. 帕金森病前驱期诊断研究标准中国专家共识[J]. 中华老年医学杂志, 2019, 38(8): 825-831.
[8] WANG X, ZHANG Y, ZHU C, et al. The diagnostic value of SNpc using NM-MRI in Parkinson's disease: meta-analysis[J]. Neurol Sci, 2019, 40(12): 2479-2489.
[9] CHENG Z, ZHANG J, HE N, et al. Radiomic features of the nigrosome-1 region of the substantia nigra: using quantitative susceptibility mapping to assist the diagnosis of idiopathic Parkinson's disease[J]. Front Aging Neurosci, 2019, 11: 167.
[10] MAHLKNECHT P, KRISMER F, POEWE W, et al. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease[J]. Mov Disord, 2017, 32(4): 619-623.
[11] ATKINSON-CLEMENT C, PINTO S, EUSEBIO A, et al. Diffusion tensor imaging in Parkinson's disease:review and meta-analysis[J]. Neuroimage Clin, 2017, 16: 98-110.
[12] ORIMO S, SUZUKI M, INABA A, et al. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative Parkinsonism: a systematic review and meta-analysis[J]. Parkinsonism Relat Disord, 2012, 18(5): 494-500.
[13] ROUSSAKIS A A, PICCINI P, POLITIS M. Clinical utility of DaTscan^TM (123I-ioflupane injection) in the diagnosis of parkinsonian syndromes[J]. Degener Neurol Neuromuscul Dis, 2013, 3: 33-39.
[14] BALLANGER B, KLINGER H, ECHE J, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease[J]. Mov Disord, 2012, 27(1): 84-89.
[15] ISHIBASHI K, MIURA Y, WAGATSUMA K, et al. Occupancy of adenosine A_2A receptors by istradefylline in patients with Parkinson's disease using ¹¹C-preladenant PET[J]. Neuropharmacology, 2018, 143: 106-112.
[16] XIANG J, TAO Y, XIA Y, et al. Development of an α-synuclein positron emission tomography tracer for imaging synucleinopathies[J]. Cell, 2023, 186(16): 3350-3367.e19.
[17] FAYYAD M, SALIM S, MAJBOUR N, et al. Parkinson's disease biomarkers based on α-synuclein[J]. J Neurochem, 2019, 150(5): 626-636.
[18] HONG Z, SHI M, CHUNGK A, et al. DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease[J]. Brain, 2010, 133(3): 713-726.
[19] ROSSI M, CANDELISE N, BAIARDI S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies[J]. Acta Neuropathol, 2020, 140(1): 49-62.
[20] VAN RUMUND A, GREEN A J E, FAIRFOUL G, et al. α-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of Parkinsonism[J]. Ann Neurol, 2019, 85(5): 777-781.
[21] SHAHNAWAZ M, TOKUDA T, WARAGAI M, et al. Development of a biochemical diagnosis of parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid[J]. JAMA Neurol, 2017, 74(2): 163-172.
[22] LEGGIO L, VIVARELLI S, L'EPISCOPO F, et al. MicroRNAs in Parkinson's disease: from pathogenesis to novel diagnostic and therapeutic approaches[J]. Int J Mol Sci, 2017, 18(12): 2698.
[23] YANG Z, LI T, LI S, et al. Altered expression levels of microRNA-132 and Nurr1 in peripheral blood of Parkinson's disease: potential disease biomarkers[J]. ACS Chem Neurosci, 2019, 10(5): 2243-2249.
[24] WANG Y, YANG Z, LE W. Tiny but mighty: promising roles of microRNAs in the diagnosis and treatment of Parkinson's disease[J]. Neurosci Bull, 2017, 33(5): 543-551.
[25] LI T, YANG Z, LI S, et al. Alterations of NURR1 and cytokines in the peripheral blood mononuclear cells: combined biomarkers for Parkinson's disease[J]. Front Aging Neurosci, 2018, 10: 392.
[26] EIDSON L N, KANNARKAT G T, BARNUM C J, et al. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease[J]. J Neuroinflammation, 2017, 14(1): 164.
[27] CUI S S, DU J J, LIU S H, et al. Serum soluble lymphocyte activation gene-3 as a diagnostic biomarker in Parkinson's disease: a pilot multicenter study[J]. Mov Disord, 2019, 34(1): 138-141.
[28] NAIR A T, RAMACHANDRAN V, JOGHEE N M, et al. Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson's disease: a critical review[J]. J Neurogastroenterol Motil, 2018, 24(1): 30-42.
[29] PEREZ-PARDO P, DODIYA H B, ENGEN P A, et al. Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice[J]. Gut, 2019, 68(5): 829-843.
[30] SCHEPERJANS F, AHO V, PEREIRA P A B, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype[J]. Mov Disord, 2015, 30(3): 350-358.
[31] TAMBASCO N, ROMOLI M, CALABRESI P. Levodopa in Parkinson's disease: current status and future developments[J]. Curr Neuropharmacol, 2018, 16(8): 1239-1252.
[32] LI Y, VORA L K, WANG J, et al. Poly(acrylic acid)/poly(vinyl alcohol) microarray patches for continuous transdermal delivery of levodopa and carbidopa: in vitro and in vivo studies[J]. Pharmaceutics, 2024, 16(5): 676.
[33] KAYHANIAN S, BARKER R A. Dopamine cell-based replacement therapies[J]. Cold Spring Harb Perspect Med, 2024: a041611.
[34] CARTOON J, RAMALINGAM J. Dopamine dysregulation syndrome in non-parkinson's disease patients: a systematic review[J]. Australas Psychiatry, 2019, 27(5): 456-461.
[35] STOCCHI F, FOSSATI B, TORTI M. Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease[J]. Expert Opin Drug Saf, 2020, 19(9): 1155-1172.
[36] VAN WAMELEN D J, LETA V, CHAUDHURI K R, et al. Future directions for developing non-dopaminergic strategies for the treatment of Parkinson's disease[J]. Curr Neuropharmacol, 2024, 22(10): 1606-1620.
[37] KANDA T, JENNER P. Can adenosine A_2A receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson's disease?[J]. Parkinsonism Relat Disord, 2020,80(Suppl 1):S21-S27.
[38] HARIZ M, BLOMSTEDT P. Deep brain stimulation for Parkinson's disease[J]. J Intern Med,2022, 292(5): 764-778.
[39] PAFF M, LOH A, SARICA C, et al. Update on current technologies for deep brain stimulation in Parkinson's disease[J]. J Mov Disord, 2020, 13(3): 185-198.
[40] GERMANN J, GOUVEIA F V, BEYN M E, et al. Computational neurosurgery in deep brain stimulation[J]. Adv Exp Med Biol, 2024, 1462: 435-451.
[41] LANG A E, OBESO J A. Stem cell therapy for Parkinson's disease[J]. Ann Neurol, 2012, 71(2): 283.
[42] MORIZANE A. Cell therapy for Parkinson's disease with induced pluripotent stem cells[J]. Inflamm Regen, 2023, 43(1): 16.
[43] PINJALA P, TRYPHENA K P, PRASAD R, et al. CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease[J]. Biomater Res, 2023, 27(1): 46.
[44] LORENTE-PICÓN M, LAGUNA A. New avenues for Parkinson's disease therapeutics: disease-modifying strategies based on the gut microbiota[J]. Biomolecules, 2021, 11(3): 433.
[45] JIA X, WANG Q, LIU M, et al. The interplay between gut microbiota and the brain-gut axis in Parkinson's disease treatment[J]. Front Neurol, 2024, 15: 1415463.
[46] 张敏娜,王宏刚,薛刘军,等. 粪菌移植治疗帕金森病的研究进展[J]. 生物工程学报, 2021, 37(11): 3812-3819.
[47] CHRISTINE C W, RICHARDSON R M, VAN LAAR A D, et al. Safety of AADC gene therapy for moderately advanced parkinson disease: three-year outcomes from the PD-1101 trial[J]. Neurology, 2022, 98(1): e40-e50.
[48] CHU Y T, TAI C H, LIN C H, et al. Updates on the genetics of Parkinson's disease: clinical implications and future treatment[J]. Acta Neurol Taiwan, 2021, 30(3): 83-93.